02-13 09:49 S.B. 274
1
Health Insurance Preauthorization Revisions
2025 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: John D. Johnson
House Sponsor:
2
3
LONG TITLE
4
General Description:
5
This bill amends provisions related to health insurance preauthorization.
6
Highlighted Provisions:
7
This bill:
8
▸ requires health insurers to provide information related to preauthorization to the
9
Department of Insurance, patients, and health care providers.
10
Money Appropriated in this Bill:
11
None
12
Other Special Clauses:
13
None
14
Utah Code Sections Affected:
15
AMENDS:
16
31A-22-650, as enacted by Laws of Utah 2019, Chapter 439
17
18
Be it enacted by the Legislature of the state of Utah:
19
Section 1. Section 31A-22-650 is amended to read:
20
31A-22-650 . Health care preauthorization requirements.
21
(1) As used in this section:
22
(a) "Adverse preauthorization determination" means a determination by an insurer that
23
health care does not meet the preauthorization requirement for the health care.
24
(b) "Authorization" means a determination by an insurer that for health care with a
25
preauthorization requirement:
26
(i) the proposed drug, device, or covered service meets all requirements, restrictions,
27
limitations, and clinical criteria for authorization established by the insurer;
28
(ii) the drug, device, or covered service is covered by the enrollee's insurance policy;
29
and
30
(iii) the insurer will provide coverage for the drug, device, or covered service subject
S.B. 274 S.B. 274 02-13 09:49
31
to the provisions of the insurance policy, including any cost sharing
32
responsibilities of the enrollee.
33
(c) "Device" means a prescription device as defined in Section 58-17b-102.
34
(d) "Drug" means the same as that term is defined in Section 58-17b-102.
35
(e) "Insurer" means the same as that term is defined in Section 31A-22-634.
36
(f) "Preauthorization requirement" means a requirement by an insurer that an enrollee
37
obtain authorization for a drug, device, or service covered by the insurance policy,
38
before receiving the drug, device, or service.
39
(2)(a) An insurer may not modify an existing requirement for authorization unless, at
40
least 30 days before the day on which the modification takes effect, the insurer:
41
(i) posts a notice of the modification on the website described in Subsection
42
31A-22-613.5(6)(a); and
43
(ii) if requested by a network provider or the network provider's representative,
44
provides to the network provider by mail or email a written notice of modification
45
to a particular requirement for authorization described in the request from the
46
network provider.
47
(b) Subsection (2)(a) does not apply if:
48
(i) complying with Subsection (2)(a) would create a danger to the enrollee's health or
49
safety; or
50
(ii) the modification is for a newly covered drug or device.
51
(c) An insurer may not revoke an authorization for a drug, device, or covered service if:
52
(i) the network provider submits a request for authorization for the drug, device, or
53
covered service to the insurer;
54
(ii) the insurer grants the authorization requested under Subsection (2)(c)(i);
55
(iii) the network provider renders the drug, device, or covered service to the enrollee
56
in accordance with the authorization and any terms and conditions of the network
57
provider's contract with the insurer;
58
(iv) on the day on which the network provider renders the drug, device, or covered
59
service to the enrollee:
60
(A) the enrollee is eligible for coverage under the enrollee's insurance policy; and
61
(B) the enrollee's condition or circumstances related to the enrollee's care have not
62
changed;
63
(v) the network provider submits an accurate claim that matches the information in
64
the request for authorization under Subsection (2)(c)(i); and
- 2 - 02-13 09:49 S.B. 274
65
(vi) the authorization was not based on fraudulent or materially incorrect information
66
from the network provider.
67
(3)(a) An insurer that receives a request for authorization shall treat the request as a
68
pre-service claim as defined in 29 C.F.R. Sec. 2560.503-1 and process the request in
69
accordance with:
70
(i) 29 C.F.R. Sec. 2560.503-1, regardless of whether the coverage is offered through
71
an individual or group health insurance policy;
72
(ii) Subsection 31A-4-116(2); and
73
(iii) Section 31A-22-629.
74
(b) If a network provider submits a claim to an insurer that includes an unintentional
75
error that results in a denial of the claim, the insurer shall permit the network
76
provider with an opportunity to resubmit the claim with corrected information within
77
a reasonable amount of time.
78
(c) Except as provided in Subsection (3)(d), the appeal of an adverse preauthorization
79
determination regarding clinical or medical necessity as requested by a physician
80
may only be reviewed by a physician who is currently licensed as a physician and
81
surgeon in a state, district, or territory of the United States.
82
(d) The appeal of an adverse determination requested by a physician regarding clinical
83
or medical necessity of a drug, may only be reviewed by an individual who is
84
currently licensed in a state, district, or territory of the United States as:
85
(i) a physician and surgeon; or
86
(ii) a pharmacist.
87
(e) An insurer shall ensure that an adverse preauthorization determination regarding
88
clinical or medical necessity is made by an individual who:
89
(i) has knowledge of the medical condition or disease of the enrollee for whom the
90
authorization is requested; or
91
(ii) consults with a specialist who has knowledge of the medical condition or disease
92
of the enrollee for whom the authorization is requested regarding the request
93
before making the determination.
94
(f) An insurer shall specify how long an authorization is valid.
95
(4)(a) An insurer that removes a drug from the insurer's formulary shall:
96
(i) permit an enrollee, an enrollee's designee, or an enrollee's network provider to
97
request an exemption from the change to the formulary for the purpose of
98
providing the patient with continuity of care; and
- 3 - S.B. 274 02-13 09:49
99
(ii) have a process to review and make a decision regarding an exemption requested
100
under Subsection (4)(a)(i).
101
(b) If an insurer makes a change to the formulary for a drug in the middle of a plan year,
102
the insurer may not implement the changes for an enrollee that is on an active course
103
of treatment for the drug unless the insurer provides the enrollee with notice at least
104
30 days before the day on which the change is implemented.
105
(5)(a) [Before April 1, 2021, and before April 1 of each year thereafter, ] Each April 1,
106
an insurer with a preauthorization requirement shall report to the department, for the
107
previous calendar year, the percentage of authorizations, not including a claim
108
involving urgent care as defined in 29 C.F.R. Sec. 2560.503-1, for which the insurer
109
notified a provider regarding an authorization or adverse preauthorization
110
determination more than one week after the day on which the insurer received the
111
request for authorization.
112
(b) Before March 1, 2026, and each March 1 thereafter, an insurer shall report to the
113
department the following for the previous calendar year:
114
(i) a list of services that have preauthorization requirements;
115
(ii) for pre-service preauthorization requests, aggregated for all services:
116
(A) the percentage of requests that were approved;
117
(B) the percentage of requests that were denied;
118
(C) the percentage of requests that were approved after appeal;
119
(D) the average and median time that elapsed between the submission of a request
120
and the final determination; and
121
(E) the percentage of requests for which the time frame for review was extended,
122
and the request was approved; and
123
(iii) for urgent preauthorization requests, aggregated for all services:
124
(A) the percentage of requests that were approved;
125
(B) the percentage of requests that were denied; and
126
(C) the average and median time that elapsed between the submission of a request
127
and the final determination.
128
(c) Subsection (5)(b) does not require an insurer to report information regarding
129
prescription drugs.
130
(d) The department shall compile the information described in Subsection (5)(b) and
131
publish the information on the department's website.
132
(6) An insurer may not have a preauthorization requirement for emergency health care as
- 4 - 02-13 09:49 S.B. 274
133
described in Section 31A-22-627.
134
(7) For each adverse preauthorization determination made by an insurer, the insurer shall
135
provide to the enrollee and the enrollee's health care provider:
136
(a) a detailed and specific explanation that explains why the determination was made;
137
and
138
(b) a notice explaining the determination may be appealed and the process for appealing
139
the determination, including how to begin an expedited appeal process as described
140
in Section 31A-22-629.
141
(8) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
142
department may make rules to implement Subsection (5)(b).
143
Section 2. Effective Date.
144
This bill takes effect on May 7, 2025.
- 5 -